Emerging aspects of Buruli ulcer

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 2, 2003, Pages 217-222

  Thangaraj, Harry S ^a   Phillips, Richard O ^a   Evans, Mark R W ^b   Wansbrough Jone, Mark H ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Department of Health ^*  (United Kingdom)

Author keywords

Amikacin; Buruli ulcer; Chemotherapy; Ciprofloxacin; Clarithromycin; Mycolactone; Rifampicin; Streptomycin

Indexed keywords

AMIKACIN; AZITHROMYCIN; BACTERIAL VACCINE; BCG VACCINE; CLARITHROMYCIN; CLOFAZIMINE; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; MESSENGER RNA; NITROGEN OXIDE; OFLOXACIN; PHENYTOIN; POLYKETIDE SYNTHASE; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL GENETICS; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BUDGET; BURULI ULCER; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DRUG PENETRATION; DRUG POTENCY; ECONOMIC ASPECT; GENETIC ANALYSIS; HEALTH CARE FINANCING; HOST SUSCEPTIBILITY; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PHOTOTOXICITY; POLYMERASE CHAIN REACTION; PRIMARY MEDICAL CARE; RECURRENT DISEASE; REVIEW; TREATMENT PLANNING; ULCER HEALING; WORLD HEALTH ORGANIZATION;

EID: 3042823399     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.2.217     Document Type: Review

References (43)

1. Thangaraj H, Evans M, Winsbrough-Jones MH. Mycobacterium ulcerans disease; Buruli ulcer. Trans. R. Soc. Trop. Med. Hyg. 93(4), 337-340 (1999).
2. Asiedu K, Scherpbier R, Raviglione M (Eds). Buruli Ulcer; Mycobacterium ulcerans Infection. WHO Publication Document: WHOCDSCPEGBUI/2000.1. (2000).
3. Amofah G, Bonsu F, Tetteh C et al. Buruli ulcer in Ghana: results of a national case search. Emerg. Infect. Dis. 8(2), 167-170 (2002).
4. Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am. J. Trop. Med. Hyg. 59 (6), 1015-1022 (1988).
5. Dobos KM, Small PL, Deslauriers M, Quinn FD, King CH. Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect. Immun. 69(11), 7182-7186 (2001).
6. George ICM, Pascopella L, Welty DM, Small PL. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea-pig ulcers and tissue culture cells. Infect. Immun. 68(2), 877-883 (2000).
7. George KM, Chatterjee D, Gunawardana G et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283(5403), 854-857 (1999).
8. Snyder DS, Small PL. Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb. Pathog. 34(2), 91-101 (2003).
9. Veitch MG, Johnson PD, Flood PE, Leslie DE, Street AC, Hayman JA. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol. Infect. 119(3), 313-318 (1997).
10. Debacker M, Zinsou C, Aguiar J, Meyers W, Portaels F. Mycobacterium ulcerans disease (Buruli ulcer) following human bite. Lancet 360(9348), 1830 (2002).
11. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 353(9157), 986 (1999).
12. Roberts B, Hirst R. Immunomagnetic separation and PCR for detection of Mycobacterium ulcerans. J. Clin. Microbiol. 35(10), 2709-2711 (1997).
13. Stinear T, Davies JK, Jenkin GA, Hayman JA, Oppedisano F, Johnson PD. Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl. Environ. Microbiol. 66(8), 3206-3213 (2000).
14. Marsollier L, Robert R, Aubry J et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl. Environ. Microbiol. 68(9), 4623-4628 (2002).
15. Marsollier L, Aubry J, Saint Andre JP et al. Ecology and transmission of Mycobacterium ulcerans. Presentation at 6th WHO Ad Hoc Advisory Group Meeting on Buruli Ulcer, Geneva, Switzerland, (2003).
16. Stinear T, Ross BC, Davies JK et al. Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J. Clin. Microbiol. 37(4), 1018-1023 (1999).
17. Russell FM, Starr M, Hayman J, Curtis N, Johnson PD. Mycobacterium ulcerans infection diagnosed by polymerase chain reaction. J. Paediatr. Child Health 38 (3), 311-313 (2002).
18. Portaels F, Aguiar J, Debacker M et al. Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin. Diagn. Lab. Immunol. 9(6), 1389-1391 (2002).
19. Amofah G, Asamoah S, Afram-Gyening C. Effectiveness of excision of pre-ulcerative Buruli lesions in field simations in a rural district in Ghana. Trop. Doct. 28(2), 81-83 (1998).
20. Portaels F, Traore H, De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42(8), 2070-2073 (1998).
21. Johnson PA. Protocol to study the protective effect of a second dose of BCG on the incidence and severity of Buruli ulcer. Presentation at 6th WHO Ad Hoc Advisory Group Meeting on Buruli Ulcer, Geneva, Switzerland, (2003).
22. Gooding T, Johnson P, Smith M, Kemp A, Robins-Browne R. Cytokine profiles of pathients infected with Mycobacterium ulcerans and unaffected household contacts. Infect. Immun. 70(10), 5562-5567 (2002).
23. Gooding T, Johnson P, Campbell D et al. Immune response to infection with Mycobacterium ulcerans. Infect. Immun. 69(3), 1704-1707 (2001).
24. Chemlal K, Huys G, Laval F et al. Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J. Clin. Microbiol. 40(7), 2370-2380 (2002).
25. Stinear TP, Jenkin GA, Johnson PD, Davies JK. Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J. Bacteriol. 182(22), 6322-6330 (2000).
26. Chemlal K, Huys G, Fonteyne PA et al. Evaluation of PCR-restriction profile analysis and IS2404 restriction fragment length polymorphism and amplified fragment length polymorphism fingerprinting for identification and typing of Mycobacterium ulcerans and M. marinum. J. Clin. Microbiol. 39(9), 3272-3278 (2001).
27. Bull TJ, Hermon-Taylor J, Pavlik I, El-Zaatari F, Tizard M. Characterization of IS900 loci in Mycobacterium avium subsp. paratuberculosis and development of multiplex PCR typing. Microbiology 146(9), 2185-2197 (2000).
28. Mve-Obiang A, Lee RE, Portaels F, Small PL. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infict. Immun. 71(2), 7741-783 (2003).
29. Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect. Immun. 69(9), 5403-5411 (2001).
30. Stinear T, Garnier T. Brosch R et al. Genome sequence analysis of Mycobacterium ulcerans. Presentation at 6th WHO Ad Hoc Advisory Group Meeting on Buruli Ulcer, Geneva, Switzerland, (2003).
31. Small PLC, Alford T, Mve-Obiang A. Development of a genetic system for use in Mycobacterium ulcerans: identification of genes required for biosynthesis of mycolactone. Presentation at 6th WHO Ad Hoc Advisory Group Meeting on Buruli Ulcer, Geneva, Switzerland, (2003).
32. Revill WD, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2(7834), 873-877 (1973).
33. Portaels F, Traore H, De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42(8), 2070-2073 (1988).
34. Thangaraj HS, Adjei O, Allen BW et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J. Antimicrob. Chemother. 45 (2), 231-233 (2000).
35. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 44 (9), 2367-2372 (2000).
36. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45(11), 3109-3112 (2001).
37. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J. Bactericidal activity of rifampinamikacin against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 46(10), 3193-3196 (2002).
38. Etuaful S, Carbonnelle J, Grosset J et al. Bactericidal activity of rifampicin and streptomycin treatment for early human M.ulcerans lesions. Presentation at 6th WHO Ad Hoc Advisory Group Meeting on Buruli Ulcer, Geneva, Switzerland, (2003).
39. Alangaden GJ, Lerner A. The clinical use of fluoroquinolones for the treatment of mycobacterium diseases. Clin. Infectious Dis. 25, 1213-1221 (1997).
40. Marsollier L, Honore N, Legras P et al. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob. Agents Chemother. 47(4), 1228-1232 (2003).
41. Adjei O, Evans MR, Asiedu A. Phenytoin in the treatment of Buruli ulcer. Trans. R. Soc. Top. Med. Hyg. 92(1), 108-109 (1998).
42. Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M. Treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides - a randomised double-blinded trial. (2003) (In Press).
43. Phillips R, Kuijper S, Benjamin M et al. In vitro antimicrobial activity of acidified nitrite on Mycobacterium ulcerans. Presentation at 6th WHO Ad Hoc Advisory Group Meeting on Buruli Ucer, Geneva, Swizerland, (2003).